Core Viewpoint - Weisi Medical (688580) has experienced a decline in stock price, with a current market capitalization of 4.587 billion yuan, ranking 79th in the medical device sector and 3616th in the A-share market [1] Group 1: Stock Performance - As of November 14, 2025, Weisi Medical's stock closed at 47.9 yuan, down 2.68% from the previous week [1] - The stock reached a high of 50.25 yuan on November 10 and a low of 47.36 yuan on November 13 [1] Group 2: Shareholder Changes - On November 12, 2025, Weisi Medical announced that shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) reduced its holdings by 448,600 shares, accounting for 0.4684% of the total share capital, during a period when the stock price fell by 7.58% [2] - From August 14 to November 11, 2025, the same shareholder reduced its holdings by a total of 1,176,782 shares, representing 1.2287% of the total share capital, with a reduction price range of 45.00 to 57.50 yuan per share, totaling approximately 59.52 million yuan [3][4] - The shareholder's stake decreased from 8.29% to 7.06%, and the actual reduction aligned with the previously disclosed plan [3][4]

Trading Information Summary - On November 12, 2025, Weisi Medical (688580) closed at 48.2 yuan, with a slight increase of 0.06% and a turnover rate of 1.97% [1] - The trading volume was 18,800 shares, with a total transaction value of 91.6083 million yuan [1] - On the same day, the net inflow of main funds was 15.4231 million yuan, accounting for 16.84% of the total transaction value [3] Shareholder Changes - On November 12, 2025, Weisi Medical announced that shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) reduced its holdings by 448,600 shares between November 5 and November 11, representing 0.4684% of the company's total share capital [2] - The share price during this period decreased by 7.58%, closing at 48.17 yuan on November 11 [2] - From August 14 to November 11, the shareholder cumulatively reduced its holdings by 1,176,782 shares, accounting for 1.2287% of the total share capital, with a reduction price range of 45.00 to 57.50 yuan per share, totaling approximately 59.516 million yuan [2][3]

Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Weisi Medical, indicating the amount and method of shares sold, as well as the overall impact on the company's total share capital [1][3]. Summary by Sections Shareholder Reduction Overview - The shareholder, Nanjing Zhida Venture Capital Center (Limited Partnership), held 7,935,120 shares prior to the reduction, representing 8.29% of the total share capital of Weisi Medical [2]. Implementation Results of the Reduction Plan - The reduction plan was disclosed on July 23, 2025, with a timeframe set from August 14, 2025, to November 11, 2025. The shareholder planned to reduce up to 2,873,137 shares, which would account for a maximum of 3% of the total share capital. This included a maximum of 957,712 shares through centralized bidding (1% of total shares) and 1,915,425 shares through block trading (2% of total shares) [3]. - The actual reduction results showed that from August 14 to November 11, 2025, the shareholder reduced 956,052 shares through centralized bidding (0.9983% of total shares) and 220,730 shares through block trading (0.2305% of total shares), totaling 1,176,782 shares, which is 1.2287% of the total share capital [3][4]. Additional Information - The reduction plan was fully implemented as planned, with no early termination of the plan [4].

Core Viewpoint - Weisi Medical announced the completion of the share reduction plan by its shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) on November 12, as confirmed in a response to investor inquiries on the interactive platform [1] Group 1 - The share reduction plan by Nanjing Zhida Venture Capital Center has reached its deadline and is now concluded [1]

Core Viewpoint - Weisi Medical announced a significant share reduction by its shareholder Nanjing Zhida Venture Capital Center, indicating potential shifts in shareholder structure and market sentiment [1] Summary by Category Shareholder Actions - Zhida Venture Capital reduced its holdings in Weisi Medical by a total of 1,176,782 shares, which represents 1.2287% of the company's total share capital [1] - The reduction occurred between August 14, 2025, and November 11, 2025, with 956,052 shares sold through centralized bidding, accounting for 0.9983% of the total share capital, and 220,730 shares sold via block trading, representing 0.2305% of the total share capital [1]

Core Viewpoint - Weisi Medical announced a significant share reduction by its shareholder Zhida Venture Capital, which may impact the company's stock performance and investor sentiment [1] Group 1: Shareholder Activity - Zhida Venture Capital reduced its holdings in Weisi Medical by approximately 960,000 shares through centralized bidding, accounting for 0.9983% of the company's total share capital [1] - Additionally, Zhida Venture Capital sold about 220,000 shares via block trading, representing 0.2305% of the total share capital [1] - The reduction period for this shareholding plan spanned from August 14, 2025, to November 11, 2025, and has now concluded [1] Group 2: Financial Performance - For the year 2024, Weisi Medical's revenue composition is as follows: medical devices accounted for 95.03%, other businesses for 3.79%, and additional services for 1.18% [1] - As of the announcement date, Weisi Medical's market capitalization stands at 4.6 billion yuan [1]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-042 南京伟思医疗科技股份有限公司 关于股东减持股份计划时间届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东持股的基本情况 本次减持计划实施前，南京伟思医疗科技股份（以下简称"伟思医疗"或"公 司"）股东南京志达创业投资中心（有限合伙）（以下简称"志达创投"）持有公 司股份 7,935,120 股，占公司总股本的 8.29%。上述股份均来源于公司 IPO 前取 得的股份以及公司实施资本公积金转股本取得的股份，均已解禁上市流通。 减持计划的实施结果情况 2025 年 7 月 23 日，公司于上海证券交易所（www.sse.com.cn）披露了《股 东减持股份计划公告》（公告编号：2025-27），志达创投计划于 2025 年 8 月 14 日至 2025 年 11 月 11 日期间，通过集中竞价、大宗交易方式减持公司股份，合 计减持不超过 2,873,137 股，合计减持比例不超过公司总股本的 3%。 ...

Core Viewpoint - Weisi Medical (688580.SH) announced a share reduction by its shareholder Zhida Venture Capital, which has implications for the company's stock performance and investor sentiment [1] Summary by Category Shareholder Actions - Zhida Venture Capital reduced its holdings in Weisi Medical by a total of 1,176,800 shares, which represents 1.2287% of the company's current total share capital [1] - The reduction occurred between August 14, 2025, and November 11, 2025, through both centralized bidding and block trading methods [1] Share Reduction Details - Specifically, Zhida Venture Capital sold 956,100 shares via centralized bidding, accounting for 0.9983% of the total share capital [1] - Additionally, 220,700 shares were sold through block trading, representing 0.2305% of the total share capital [1]

Core Insights - Weisi Medical's stock price increased by 2.14% on November 12, reaching 49.20 CNY per share, with a market capitalization of 4.712 billion CNY [1] - The company has seen an 81.48% increase in stock price year-to-date, but has experienced a decline of 3.40% over the last five trading days [1] Company Overview - Nanjing Weisi Medical Technology Co., Ltd. was established on January 10, 2001, and went public on July 21, 2020 [2] - The company specializes in the research, development, production, and sales of rehabilitation medical devices, focusing on areas such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [2] - Revenue composition includes: magnetic stimulation (39.44%), consumables and accessories (19.42%), electrophysiology (19.18%), laser radiofrequency (10.26%), electrical stimulation (8.42%), and others (3.28%) [2] Financial Performance - For the period from January to September 2025, Weisi Medical reported revenue of 326 million CNY, a year-on-year increase of 11.58%, and a net profit attributable to shareholders of 102 million CNY, a year-on-year growth of 30.68% [2] - The company has distributed a total of 386 million CNY in dividends since its A-share listing, with 226 million CNY distributed over the past three years [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Views - The medical device and medical services sectors have shown strong revenue performance, while the chemical preparation sector has experienced year-on-year net profit growth [2][21]. - The pharmaceutical and biotechnology sector achieved a revenue of CNY 1,825.74 billion in the first three quarters of 2025, a year-on-year decrease of 1.97%, with a net profit of CNY 139.66 billion, down 1.59% year-on-year [2][21]. - The report emphasizes the importance of clinical value in investment strategies, suggesting a focus on innovative drug and medical device sectors [3][35]. Summary by Sections Market Review - The pharmaceutical and biotechnology index fell by 2.40%, underperforming the CSI 300 index by 3.22 percentage points, ranking 29th among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index also declined by 2.62%, lagging behind the Hang Seng National Enterprises Index by 3.7 percentage points [1][16]. Financial Performance - In Q3 2025, the pharmaceutical sector reported a revenue of CNY 598.54 billion, a year-on-year increase of 0.78%, and a net profit of CNY 40.51 billion, up 7.67% year-on-year [2][21]. - The gross profit margin for the pharmaceutical sector was 31.4%, down 1.4 percentage points year-on-year [2][21]. Sector Analysis - The medical device sector saw a significant revenue increase of 10.65% in Q3 2025, attributed to a recovery in domestic bidding [22]. - The chemical preparation sector's revenue decreased by 0.82% in Q3 2025, but net profit increased by 5.05%, driven by strong performance from leading innovative drug companies [21][22]. - The CXO (Contract Research Organization) sub-sector showed robust growth, with a revenue increase of 10.93% and a net profit increase of 47.90% in Q3 2025 [22]. Investment Strategy - The report advocates for investments in innovative drug chains and high-end medical devices, highlighting companies such as Innovent Biologics, Eifang Biologics, and Mindray Medical [7][37]. - The report suggests that the pharmaceutical sector's valuation is recovering, with a focus on clinical value driving future investments [35][36].